Wisconsin Collaborative for Quality Healthcare

View Our Reports

print this page

Ischemic Vascular Disease: Daily Aspirin or Other Antiplatelet Therapy Unless Contraindicated This is a measure developed by the Wisconsin Collaborative for Healthcare Quality (WCHQ).


The results below represent the care of 87,882 patients with coronary and other atherosclerotic vascular disease. Read More About This Measure

Reporting Period:

Sort By Rank | Sort By Name  

There has been important evidence from clinical trials that further supports and broadens the merits of risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease.

Based on trials involving other secondary prevention therapies, the ACC and AHA recommends aspirin in all patients, unless contraindicated, with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. The ACC and AHA also recommend the use of other antiplatelet agents based on disease type and clinical conditions.

This measure shows the percentage of people 18 to 75 years of age with a diagnosis coronary or other atherosclerotic vascular disease who were prescribed oral antiplatelet therapy, unless contraindicated, in the measurement year.


Disclaimer: Measures reported by WCHQ healthcare organizations represent a specific aspect of care in relation to an evidence-based standard, but are not clinical guidelines and do not establish standards of care.